Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Retinoblastoma 1Neuroblastoma 1Medulloblastoma 1Glioblastoma 1Carcinoid Tumor 1

Interventions

Bevacizumab 5pembrolizumab 3Paclitaxel 3fludarabine 2Sorafenib 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1durvalumab 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1belzutifan 1aflibercept 1abiraterone 1Thalidomide 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Biological Factors × Genitourinary × Clear all
NCT00314925 2010-02-25

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Neotropix

Phase 1 Unknown
60 enrolled
CNSEndocrineGenitourinaryOther solid neoplasmSarcoma

Carcinoid Tumor, Glioblastoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡